c-Met: A Promising Therapeutic Target in Bladder Cancer

被引：13

作者：

Feng, Yanfei ^{[1
]}

Yang, Zitong ^{[2
]}

Xu, Xin ^{[2
,3
]}

机构：

[1] Zhejiang Chinese Med Univ, Affiliated Coll 2, Hangzhou, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Hangzhou, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, 79th Qingchun Rd, Hangzhou 310003, Peoples R China

来源：

CANCER MANAGEMENT AND RESEARCH | 2022年 / 14卷

基金：

中国国家自然科学基金;

关键词：

c; -Met; HGF; noncoding RNA; bladder cancer; review; HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; URINARY-BLADDER; SCATTER FACTOR; PROGNOSTIC INDICATOR; LUNG ADENOCARCINOMA; EXPRESSION; MIGRATION;

D O I：

10.2147/CMAR.S369175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor family and is overexpressed in various human cancers. Its ligand is hepatocyte growth factor (HGF), and the HGF/c-Met signaling pathway is involved in a wide range of cellular processes, including cell proliferation, migration, and metastasis. Emerging studies have indicated that c-Met expression is strongly associated with bladder cancer (BCa) development and prognosis. Therefore, c-Met is a potential therapeutic target for BCa treatment. Recently, the aberrant expression of noncoding RNAs was found to play a significant role in tumour progression. There is a close connection between c-Met and noncoding RNA. Herein, we summarized the biological function and prognostic value of c-Met in BCa, as well as its potential role as a drug target. The relation of c-Met and ncRNA was also described in the paper.

引用

页码：2379 / 2388

页数：10

共 50 条

[1] HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers
Zhang, Hongli
Feng, Qingqing
Chen, Wei-Dong
Wang, Yan-Dong
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
[2] c-Met Signaling as a Therapeutic Target in Head and Neck Cancer
Centuori, Sara M.
Bauman, Julie E.
CANCER JOURNAL, 2022, 28 (05): : 346 - 353
[3] c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, JG
Burrows, J
Salgia, R
CANCER LETTERS, 2005, 225 (01) : 1 - 26
[4] c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
Li, Chenwei
Wu, Jing-Jiang
Hynes, Mark
Dosch, Joseph
Sarkar, Bedabrata
Welling, Theodore H.
di Magliano, Marina Pasca
Simeone, Diane M.
GASTROENTEROLOGY, 2011, 141 (06) : 2218 - U395
[5] C-met as a therapeutic target for metastatic potential of gastric cancer.
Cho, H.
Zhang, X.
Jung, M.
Kwon, W.
Jung, J.
Jeung, H.
Roh, J. K.
Chung, H. C.
Rha, S. Y.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[6] c-Met: a New Cancer Stem Cell Marker and Therapeutic Target for Pancreatic Cancer
Wu, J-J.
Li, C.
Hynes, M.
Dosch, J.
Sarkar, B.
Magliano, M. P.
Simeone, D. M.
PANCREAS, 2011, 40 (08) : 1363 - 1363
[7] Activated c-Met; a Potential Therapeutic Target in Chordoma
Riddle, Nicole
Jones, Krister
Staddon, Arthur
Zhang, Paul
Brooks, John
Huang, Jui-Han
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 : A303 - A303
[8] c-Met: A potential therapeutic target for hepatocellular carcinoma
Gao, Jianjun
Inagaki, Yoshinori
Xue, Xia
Qu, Xianjun
Tang, Wei
DRUG DISCOVERIES AND THERAPEUTICS, 2011, 5 (01): : 2 - 11
[9] SIGNIFICANCE OF C-MET AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
Kashiwagi, S.
Yashiro, M.
Aomatsu, N.
Kawajiri, H.
Takashima, T.
Onoda, N.
Ishikawa, T.
Hirakawa, K.
ANNALS OF ONCOLOGY, 2012, 23 : 84 - 84
[10] Identification of c-Met as downstream of γ-glutamylcyclotransferase (GGCT), a novel therapeutic target for cancer
Taniguchi, Keiko
Saito, Yumiko
Ii, Hiromi
Horinaka, Mano
Kageyama, Susumu
Nakata, Susumu
Ukimura, Osamu
Sakai, Toshiyuki
CANCER SCIENCE, 2025, 116 : 159 - 159

← 1 2 3 4 5 →